**Bio-Techne Corporation (TECH)** has been an active player, despite multiple market headwinds. The company's position was boosted by **US Bancorp DE** and also saw an increase in shares by **Jensen Investment Management Inc.** and **Dimensional Fund Advisors LP**. **TECH** also demonstrated merit by highlighting several applications of the **MauriceFlex™ System** at the **Annual ASMS**. However, Q4 results were relatively weak. The company has declared dividends and their shares projections are 32% and 25% above intrinsic value estimates. However, the positioning by **Teacher Retirement System of Texas** saw a decrease. Presentations at **Leerink Partners Healthcare Crossroads Conference** and **2024 AACR** reflect TECH's visibility. **BI Asset Management Fondsmaeglerselskab A S** and **Victory Capital Management Inc** also bought shares, demonstrating investor confidence. THE stocks page indicates a mixed Q2 fiscal amid industry headwinds and Citi downgrades TECH to neutral, citing valuation. Announcements of new distribution agreements with **Thermo Fisher Scientific**, a partnership with **Nikon Instruments Inc.**, and **Novomol-Dx** represent significant collaborations. Furthermore, an announcement for a **$20 Million G-Rex® Grant Program for Advance of Cell and Gene Therapy** by **ScaleReady** is a significant indicator of TECH's role in the sector.
Bio-Techne Corp TECH News Analytics from Thu, 04 Aug 2022 07:00:00 GMT to Thu, 30 May 2024 11:00:00 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -2
